Last updated: April 23, 2026
Who supplies buprenorphine hydrochloride API?
Buprenorphine hydrochloride (often marketed as buprenorphine HCl or buprenorphine hydrochloride) is supplied by a mix of brand-linked manufacturers, dedicated API producers, and regional specialty chemical companies that produce either the API directly or key precursors (used to make the API under contract manufacturing).
Which suppliers are active in buprenorphine hydrochloride (API) supply?
Commercial API supply (global manufacturers and specialty API producers)
The list below reflects companies that are publicly associated with buprenorphine HCl API manufacturing and/or regulated API distribution:
| Supplier |
Typical role in the value chain |
Indications of public association |
| Siegfried (Switzerland) |
API producer (contract and in-house) |
Company product and regulatory footprint for buprenorphine-related substances in controlled markets (company and regulatory records). |
| Lupin (India) |
API producer |
Public API catalog presence for buprenorphine hydrochloride and generic product supply linkage. |
| Dr. Reddy’s (India) |
API producer |
Public generic and API manufacturing footprint; buprenorphine HCl appears in product portfolios tied to controlled substance filings. |
| Teva (Israel/Global) |
Branded/generic manufacturer (often vertically integrated) |
Public portfolio for buprenorphine products; supply chain often includes API manufacturing and/or qualified sources. |
| Braun (Germany, through pharma segment/supply contracts) |
Finished dose producer and supply partner |
Public supply involvement in buprenorphine-containing products; often ties to qualified API sourcing. |
| STADA (Germany) |
Finished dose supplier (and potential qualified API sourcing) |
Public buprenorphine product presence in European markets. |
| Mylan/Viatris (US/Global) |
Finished dose supplier with API supply chain presence |
Public buprenorphine product filings imply qualified API sourcing. |
Which suppliers sell buprenorphine hydrochloride in the form of “substance for pharmaceutical use”?
A subset of suppliers sells buprenorphine HCl as a pharmaceutical substance (API-grade or research-use grade, depending on customer compliance). These vendors typically qualify customers under controlled-substance handling rules.
Substance and specialty-chemical vendors (often API-grade or near-API grade)
These companies are commonly found in procurement pathways for buprenorphine HCl and related controlled opiate substances:
- BASF / Merck / Sigma-Aldrich (research and supply channels depending on jurisdiction)
- Santa Cruz Biotechnology / Thermo Fisher Scientific (select catalog listings; jurisdiction- and license-dependent)
- Alfa Aesar / TCI (catalog listings where permitted)
In regulated pharmaceutical procurement, these are less common than dedicated API manufacturers, but they appear in lab and development sourcing.
What intermediates or process inputs determine which suppliers matter?
Buprenorphine hydrochloride supply depends on whether you buy:
- Final API (buprenorphine HCl)
- Buprenorphine base (free base) + conversion to HCl
- Key precursors used in the semisynthesis route
Common upstream routes in the industry use norcoclaurine derivatives and subsequent transformations toward buprenorphine skeleton formation, followed by salt formation with hydrochloric acid to produce buprenorphine hydrochloride. The practical supplier set changes depending on whether a vendor sells the salt directly or provides buprenorphine free base.
What quality/regulatory footprint governs supplier selection?
For pharmaceutical use, supplier qualification typically targets:
- GMP manufacturing (for API)
- DMF/ASMF submission presence where applicable (US and EU routes)
- Controlled substance compliance for opiate APIs
- Analytical package (CoA, impurity profile, particle specs)
- Stability and shipping controls
A buyer’s fastest route is usually a vendor with established US DMF/ASMF alignment or a finished-dose manufacturer that can provide qualified API via procurement channels.
How to shortlist suppliers for buprenorphine hydrochloride (actionable procurement screen)
Use a qualification filter aligned to pharmaceutical procurement rather than lab sourcing:
- GMP API status (not just catalog availability)
- Regulatory documentation: DMF/ASMF for the exact material form (salt, polymorph, and grade)
- Controlled substance licensing capability for import, warehousing, and release
- Batch consistency: impurity profile and residual solvent compliance
- Supply continuity: number of recent commercial batches and capacity disclosure in vendor audits
Key Takeaways
- Buprenorphine hydrochloride supply runs through dedicated API manufacturers plus vertically integrated branded/generic companies with qualified procurement networks.
- Supplier choice depends more on GMP and regulatory documentation (DMF/ASMF and controlled-substance compliance) than on generic “chemical supplier” availability.
- Buyers should shortlist vendors with proven GMP API production and stable controlled-substance logistics for uninterrupted supply.
FAQs
1) Can I buy buprenorphine hydrochloride from general chemical distributors?
Often yes for non-clinical research channels, but for pharmaceutical supply the controlling factor is GMP grade and regulatory package plus controlled-substance compliance.
2) Is buprenorphine hydrochloride always supplied as the HCl salt?
Many suppliers offer buprenorphine base and convert to HCl, while others supply the HCl salt directly. The chosen option affects qualification scope and impurity profile.
3) What documents should I expect from an approved API supplier?
Typically an API CoA, impurity/assay profile, and evidence of GMP manufacture. For regulated filings, expect DMF/ASMF coverage tied to the exact API form.
4) Do supplier lists differ by region?
Yes. Availability and licensing differ across the US, EU, UK, and Asia due to controlled-substance handling rules and filing pathways.
5) What drives supplier risk for buprenorphine HCl?
Controlled substance logistics, regulatory status of the manufacturing site, and consistent impurity control across batches.
References
[1] US FDA. “Drug Master Files (DMF).” FDA.gov.
[2] European Medicines Agency. “Assessment reports and regulatory documents for Active Substance Master File (ASMF) and API quality.” EMA.europa.eu.
[3] WHO. “Narcotic Drugs and Psychoactive Substances: Availability and control mechanisms.” WHO.int.
[4] ICH. “Q3A(R2) Impurities in New Drug Substances” and “Q3B(R2) Impurities in New Drug Products.” Ich.org.
[5] DEA. “Controlled Substances: Registration and handling requirements.” DEA.gov.
